Ardsley Advisory Partners’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Ardsley Advisory Partners’s Portfolio FOMX Stock Details FOMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-10,000	Closed	-$103K	–	206
2015 Q2	$103K	Sell	10,000 -10,000	-50%	-$111K	0.01%	158
2015 Q1	$185K	Buy	20,000 +10,000	+100%	+$89.5K	0.03%	172
2014 Q4	$70K	Buy	+10,000	New	+$57.2K	0.01%	177

Other funds holding FOMX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Ardsley Advisory Partners's FOMX Position: Q3 2015 in Review

Ardsley Advisory Partners sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q3 2015, closing a stake of 10,000 shares — an estimated $103K sold.

Ardsley Advisory Partners first reported a position in FOMX in Q4 2014 and held it in 3 quarters. The position peaked at $185K in Q1 2015. 77 funds tracked by Wall St. Rank hold FOMX as of Q3 2015.

Ardsley Advisory Partners reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q3 2015 after selling out during the quarter.
Ardsley Advisory Partners sold 10,000 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q3 2015, an estimated $103K.
Ardsley Advisory Partners first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q4 2014 and held it in 3 quarters.
Ardsley Advisory Partners's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $185K in Q1 2015.
77 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q3 2015.

Based on Ardsley Advisory Partners's 13F filing for Q3 2015, filed 16 Nov 2015.